With the increase of human life span and the increasing of natural cancer-causing factors, the incidence of gynecologic malignant tumors is increasing year by year, which seriously endangers the life and health of women. The development of oncology therapeutics in recent years, including the improvement of radiotherapy and surgery techniques, the discovery and standardized use of new chemotherapeutic drugs and anti-cancer drugs, has strongly improved the treatment situation of gynecological cancer. It is reported that for middle and late stage gynecological malignant tumors, the infiltration of tumor cells into surrounding organs makes surgery inoperable or difficult, and conventional intravenous chemotherapy cannot effectively kill cancer cells due to low local drug concentration in cancer tissues, so it is difficult to achieve satisfactory results with traditional treatments. In response to this problem, foreign scholars first applied vascular interventional therapy to mid- to late-stage gynecologic malignancies in the 1960s and achieved certain efficacy, and then through more than 40 years of in-depth basic and clinical research, its therapeutic effects on gynecologic cancers were confirmed, and vascular interventional therapy has been applied to various types of gynecologic malignancies, becoming an effective supplement to traditional treatment. Interventional therapy can be applied to neoadjuvant chemotherapy before gynecologic cancer surgery, aiming at eliminating micro metastases and subclinical foci around cancer foci to make surgical resection more complete; at the same time, it can be administered before blood vessels and lymphatic vessels at all levels of the tumor are damaged to increase the concentration of local chemotherapeutic drugs to achieve efficient killing of cancer cells; it can also shrink tumor foci to reduce surgical complications, or enable patients with mid- to late-stage gynecologic cancer who have lost the opportunity of surgery to obtain surgery. It can also shrink tumor lesions and reduce surgical complications, or enable patients with mid- to late-stage gynecological cancer who have lost the chance of surgery to have the opportunity of surgery and create conditions for follow-up treatment. Interventional therapy can also be used as palliative treatment for postoperative recurrence of gynecologic cancer, which has the advantages of minimally invasive and reproducible. For certain gynecological malignancies, such as trophoblastic tumors, interventional therapy can also be used as a radical treatment. Interventional therapy can be applied to various types of gynecologic malignant tumors in various stages and can be divided into the following indications according to their purposes: (1) preoperative neoadjuvant chemotherapy: mainly used for vulvar, vaginal, cervical, ovarian and endometrial cancers; (2) palliative treatment for postoperative recurrence: mainly used for vulvar, vaginal, cervical, ovarian and endometrial cancers. (3) Radical treatment: mainly for malignant trophoblastic tumors; (4) Hemostatic treatment for bleeding caused by gynecologic malignancies and bleeding complicated by radiotherapy; (5) Intra-iliac arteriovenous fistula caused by gynecologic malignancies. Contraindications: (1) patients with systemic metastases and patients with systemic failure; (2) patients with contraindications to intubation such as coagulation dysfunction; (3) patients with contraindications to chemotherapy such as bone marrow suppression and liver function impairment. (2) Interventional procedures: internal iliac artery perfusion chemotherapy/embolization; uterine artery perfusion chemotherapy/embolization; ovarian artery perfusion chemotherapy/embolization. Director Yang Yan points out that regardless of the interventional procedure, the femoral artery is first punctured unilaterally, 0.5 cm below the midpoint of the inguinal ligament at the point of strongest femoral artery pulsation, and the femoral artery is punctured with Seldinger’s technique. A 4-6F vascular sheath set is selected, and a matching catheter and guidewire are used for appropriate vascular placement, followed by perfusion chemotherapy or embolization. Arterial infusion chemotherapy alone is rarely used nowadays, but usually arterial infusion chemoembolization is used, in which 2/3 of the anti-cancer drug is infused first, and then the remaining 1/3 is added to the embolization agent for embolization. This can make the cancer tissues obtain a high impact concentration first, and then the slow release of the drug in the embolization agent can have a continuous killing effect on the cancer cells; at the same time, embolization of the tumor blood supply artery can make the cancer cells sensitive to blood supply ischemia and hypoxia, thus leading to their necrosis. The two complement each other to achieve a good anti-cancer effect. One of the advantages of interventional arterial perfusion chemotherapy over intravenous chemotherapy is that it increases the local anti-cancer drugs and reduces the drugs entering the peripheral blood, thus improving the efficacy of anti-cancer drugs and reducing drug side effects. To further increase the concentration of drugs at the tumor site during perfusion, boosting therapy and arterial blockade therapy can be used. The tumor vasculature is insensitive to angiotensin-II (angiotensin-II) by intravenous infusion, and the tumor vasculature is relatively dilated due to the lack of mature smooth muscle, so the blood flow into the tumor increases, and the amount of anticancer drugs entering the tumor increases accordingly. The arterial blocking method is to place a double-lumen balloon catheter in the target blood vessel and temporarily block the artery with the balloon before drug infusion, so that the drug injected through the catheter will be carried away without blood flow, and the time of stay in the tumor site will be prolonged and the concentration and effect will be increased. Arterial infusion chemotherapy is a new kind of local chemotherapy which is obviously different from traditional intravenous chemotherapy, and its medication principle and clinical pharmacokinetic principle are also different from intravenous chemotherapy. Some drugs suitable for intravenous chemotherapy are not suitable for arterial infusion chemotherapy, such as CTX, which is inactive as a transportable drug and must be metabolized by CTX enzymes in the liver to become active CTX before it can have anticancer effects; 5-Fu has only 20% tissue utilization in arterial chemotherapy, which is also not suitable for arterial chemotherapy. Based on the above principles, Carboplatin should be used in the selection of arterial infusion chemotherapeutic drugs: (1) the anti-cancer drug must have definite efficacy on the tumor; (2) the killing effect of the drug on cancer cells is in the form of prototype; (3) the anti-cancer effect of the drug is concentration-dependent; (4) the anti-cancer effect is fast and strong and can kill cancer cells rapidly. According to the above principles, Carboplatin, EADM, ADM, NH2, etc. can be used as the basic drugs for arterial chemotherapy. 4.Complications: 4.1 Complications caused by intravascular operation; 4.2 Complications caused by embolization therapy; 4.3 Complications caused by contrast agents: urticaria, skin mucous membrane flushing, gastrointestinal reactions, etc.; 5.4 Anti-cancer drug reactions: nausea, vomiting, hair loss, damage to hematopoietic system, liver and kidney functions, etc. 5.Efficacy evaluation of interventional treatment of gynecologic malignancies: can be evaluated by clinical, clinical pharmacokinetics, pathology, apoptosis and cell proliferation.